Aclaris Therapeutics Inc (NASDAQ:ACRS) shares, rose in value on Thursday, May 08, with the stock price up by 4.80% to the previous day’s close as strong demand from buyers drove the stock to $1.31.
Actively observing the price movement in the last trading, the stock closed the session at $1.25. Referring to stock’s 52-week performance, its high was $5.17, and the low was $0.95. On the whole, ACRS has fluctuated by 6.50% over the past month.
With the market capitalization of Aclaris Therapeutics Inc currently standing at about $141.85 million, investors are eagerly awaiting this quarter’s results, scheduled for in June.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ACRS’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ACRS currently trading nearly 5.48% and -10.86% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.98, while the 7-day volatility ratio is showing 7.99% which for the 30-day chart, stands at 8.49%. Furthermore, Aclaris Therapeutics Inc (ACRS)’s beta value is 0.44, and its average true range (ATR) is 0.11.
Data on historical trading for Aclaris Therapeutics Inc (NASDAQ:ACRS) indicates that the trading volumes over the past 3 months, they’ve averaged 881.55K. According to company’s latest data on outstanding shares, there are 107.85 million shares outstanding.
Nearly 15.34% of Aclaris Therapeutics Inc’s shares belong to company insiders and institutional investors own 72.35% of the company’s shares. The stock has fallen by -47.18% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ACRS stock heading into the next quarter.
